Silverarc Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Silverarc Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.3M	Buy	+1,946,482	New	+$8.68M	1.07%	32
2023 Q3	–	Sell	-219,229	Closed	-$1.87M	–	81
2023 Q2	$2.27M	Sell	219,229 -871	-0.4%	-$7.88K	0.7%	42
2023 Q1	$1.78M	Sell	220,100 -132,093	-38%	-$1.68M	0.74%	46
2022 Q4	$5.55M	Sell	352,193 -191,583	-35%	-$3.08M	1.59%	23
2022 Q3	$8.56M	Buy	543,776 +4,231	+0.8%	+$66.7K	2.9%	11
2022 Q2	$7.53M	Buy	539,545 +264,212	+96%	+$3.7M	2.32%	13
2022 Q1	$4.75M	Sell	275,333 -10,893	-4%	-$149K	1.96%	12
2021 Q4	$4.16M	Buy	286,226 +112,899	+65%	+$1.71M	1.69%	19
2021 Q3	$3.12M	Sell	173,327 -15,392	-8%	-$247K	1.76%	20
2021 Q2	$3.31M	Sell	188,719 -148,018	-44%	-$3.36M	1.48%	21
2021 Q1	$8.49M	Buy	+336,737	New	+$6.59M	4.63%	1

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Silverarc Capital Management's ACRS Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 1,946,482 shares worth $10.3M. The stake represents 1.07% of the portfolio and ranks #32 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in ACRS as recently as Q2 2023.

Silverarc Capital Management first reported a position in ACRS in Q1 2021 and has held it in 11 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Silverarc Capital Management held 1,946,482 shares of Aclaris Therapeutics worth $10.3M as of Q2 2026.
Aclaris Therapeutics was a new Silverarc Capital Management position in Q2 2026.
Aclaris Therapeutics made up 1.07% of Silverarc Capital Management's portfolio in Q2 2026, its #32 holding.
Silverarc Capital Management first reported a position in Aclaris Therapeutics in Q1 2021 and has held it in 11 quarters since.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.